DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE
Pre-Launchdolutegravir, emtricitabine and tenofovir alafenamide
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing dolutegravir (integrase strand transfer inhibitor), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor) for oral administration. The combination treats HIV-1 infection by simultaneously blocking viral integration, reverse transcription, and nucleotide incorporation. This represents a complete antiretroviral regimen in a single tablet.
PRE_LAUNCH
Pre-launch stage indicates small team size with focus on regulatory completion, manufacturing scale-up, and launch preparation activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Pre-launch phase offers career opportunities in regulatory completion, manufacturing scale-up, payer negotiations, and launch strategy—ideal for professionals seeking involvement in bringing a generic fixed-dose combination to a competitive HIV market. Limited current job openings reflect early pipeline stage; opportunities will expand significantly post-approval.
Regulatory Affairs Manager
Worked on DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.